Fortnightly Healthtech Update #17

Lengthy article on the evolution of mobile phones for digital phenotyping (ie. continual data collection of the individual). 

CareSignal (formerly Epharmix) gets funding from customers and others for remote patient monitoring. The beauty is, it’s a relatively low-tech solution that can be used by many diverse patient populations with different conditions. See studies on COPDdiabetes, and mental health. Often, simple really is better.

The direct primary care model continues to evolve with Clove Health claiming to be the first legally incorporated as a public benefit corporation getting to work in Florida. More on that style  of incorporation hereCitizen Health is heading down a similar path.

I touched on the ongoing battle over patient access to their own data. Apparently the federal government has started hitting providers with fines if they make it difficult for patients to get their data.

From Imperial College London, using sound to detect vital signs allows a device to penetrate layers of clothing.

Medicare builds on the mixed success of ACOs to create the Direct Contracting model for the next stage of value based care. There’s also the Primary Care First model, now due sometime next year. Also, a fresh study of Medicare ACOs finds that much of the cost variation comes from the use of out-of-network primary care docs.

More Medicare, the CJR program was controversially introduced as a hip and knee replacement bundle a few years ago. Controversially because it was a mandatory bundle introduced because providers didn’t sign up for the similar voluntary program with sufficient enthusiasm. Now CMS wants to extend it for another 3 years, and add in outpatient settings too. Which makes sense because it will drive the cost down, all other things being equal.

A new design to make better, cheaper biosensors for fluid analysis. Quite honestly, it works in ways I don’t fully comprehend, but hopefully it means something to some of you…

More healthcare reform, CMS picks 205 EMS services for the experimental ET3 model. The intent of ET3 is mostly to help people with chronic conditions get treated in their homes, avoiding the personal discomfort and stress of perpetual trips to the ED. It also should save Medicare money on avoidable ED visits too. To do that, ET3 allows EMS to get reimbursed for other services, not just transport. This potentially opens up another route to market for medtech vendors in applications like remote patient monitoring.

Wearables and machine learning start to show real promise: PhysIQ and VitalConnect study shows promise for predicting hospitalizations for heart failure patients. We’re already seeing machine learning breaking into imaging. I think continuous patient monitoring also has real potential. There’s a big need to determine baseline vital signs for individual patients, rather than just using generic values. I think machine learning might have the potential to usher in more adaptive algorithms that can help to reduce the long-running over alarming problem.

Apple leans hard into atrial fibrillation. A new collaboration with J&J makes the Apple Watch available for $49 to seniors who take part in a study. This could be a win for everybody: Seniors who avoid a potential stroke through the early detection of afib, cardiologists who get more business, and obviously Apple. Presumably J&J has some meds for managing afib in its portfolio too. And Medicare could win, since stroke care is reckoned to cost $40bn a year.

Sepsis has been a silent killer for a long time. A new study finds a stunning growth of 40% among Medicare beneficiaries who were hospitalized. Digging deeper into the economics, the same study finds the total cost of treating sepsis to be much higher than previously thought – over $23bn for inpatient care alone.

At the other end of the age scale, Children’s Hospital of Philadelphia has developed a new algorithm for detecting pediatric sepsis.

A new potential tool in the opioid crisis, a wearable to detect opioid induced respiratory depression (OIRD) in the community. Developed by Altair Medical in Scotland, I’m interested to see how this develops and works in practice. There are definitely challenges in current opioid addiction treatment that this could address. (For podcast fans, Freakonomics has a good two-parter on the crisis and current approaches). Also, equal parts tragic, genius, and sheer practicality, a number of communities are training kids to administer Narcan. Note, OIRD is still a major problem for post-surgical patients too, where hopefully the patients location and time to rescue are more predictable, so potentially more effective overall.

Simple early warning scoring is still an undervalued (and under adopted) practice for catching patient deterioration early. One hospital system in the UK dropped cardiac arrests by 75% by capturing vitals at the bedside with iPads and calculating the early warning score automatically. 

An unfortunate reminder that technology alone can’t change anything: WellSpan Health York Hospital gets cited for failure to respond to a patient in distress. It seems even thought the patients falling heart rate and oxygenation levels were noted for at least 20 minutes, nursing staff failed to intervene.

Fortnightly Healthtech Update #16

Walmart moves into radiology, opening a clinic in Calhoun Georgia with x-ray facilities. Which is a nice lead in to will big retail disrupt healthcare more than big tech?

Profusa’s Lumee tiny oxygen sensor gains a CE mark. Intended for conditions such as peripheral artery disease, the device operates for 28 days, clinical study here.

Apple highlights it’s healthcare presence in its earnings release, claiming 100% of F500 companies in the healthcare sector use Apple. Which sounds impressive, but when you think about it, that’s a small number. You might even be able to count those companies on the fingers of one hand. 

Medicare’s bundled payment isn’t perfect, it rewards doctor’s who take lower risk patients. Really would be nice if it worked the other way around perhaps.

The legal fight over price transparency continues. Meaningful transparent hospital pricing would lead to meaningful competition among hospitals. Competition among hospitals would lead to lower prices. Hence, the AHA is obliged to fight it on behalf of its members. But the American Academy of Family Physicians is not.

On the theme of overpaying, Medicare paid $7.8bn for insulin. If it paid the same prices as another federal government department (the VA) it would only have paid $3.4bn. That is just one of many examples of Medicare overpaying because of a lack of political will.

Verily partners up with Santen for vague eye are projects.

Continuous vital sign monitoring in hospitals is becoming a thing at glacial pace. (See Isansys in the last post). This study compares the performance of devices from EarlySenseSensiumVitalConnect, and Masimo. In summary, all are accurate for heart rate, some better than others for respiratory rate.

The lack of continuous monitoring still hits the broader headlines occasionally. In this case,  Cleveland area hospitals are highlighted for their tardy adoption following the tragic loss of a patient in 2016. 

Also continuous monitoring, continuous monitoring of urine for the early detection of kidney problems from Serenno Medical.

Virta Health – treating diabetes the old school way with diet – has been running a pilot with the VA for a year.

Scientists in Korea have developed a biosensor test for the early detection of Alzheimer’s.

An opinion piece from a Professor at Stanford University School of Medicine, outlining how a simple market segmentation would improve healthcare delivery. In practice, I think market forces are already doing this to some extent. The reasonably wealthy/reasonably healthy are starting to adopt concierge medicine, or direct primary care. But, I can’t figure out how direct primary care is going to work for the chronically ill. The direct primary care model often touts unlimited primary care access as a benefit. But, unlimited access to a primary care doc is just like having unlimited paid time off. It only works if you don’t take the “unlimited” literally. And that won’t apply to many chronically ill people with multiple comorbidities of course. And if that mild criticism wasn’t enough for you, Molly Osberg well and truly shreds direct primary care – the comments are definitely worth a read too.

Oh, and Iora Health, one of the pioneers for direct primary care, just closed $126m in funding.

Apple finds itself squaring up to Epic and assorted hospitals in the fight to allow patients to easily access and share their healthcare data. Epic and friends voice concerns about patient privacy. But, dig deeper. Allowing Apple access to health records is a long-term threat to Epic’s dominant position in the EMR business. And, as noted above (on price transparency), hospitals aren’t keen on competition either. Preventing people from easily moving their data from one provider to another is just one more way to lock in a patient’s revenue stream. Which is really unfortunate. Because, if consumers had better access to quality data, better access to pricing, and could easily move their health records from one provider to another, hospitals that delivered greater value to consumers would ultimately thrive. And those that did not would either raise their game or wither and die. Everybody wins – except sucky hospitals.

Also in the EMR connectivity game, Innovaccer raises $70m to create longitudinal patient records to support the transition to value-based care. I imagine it will find “patient privacy concerns” to be a challenge too. 

Caretaker Medical of finger-cuff blood pressure fame, adds ECG via a partnership with VivaLNK. Ditto VitalConnect, partnering with CorVitals to add arrhythmia detection.

Researchers in New South Wales come up with a superior algorithm for early detection of sepsis.

Machine learning is steadily making inroads into the diagnostic space. PhysIQ adds a patent to estimate cardiopulmonary function from wearables.

Challenging assumptions or a little Christmas humor…Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.